Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL: Lasofoxifene in Postmenopausal Osteoporosis
NCT00141323Phase 3Completed
- Sponsor
- Ligand Pharmaceuticals
- Start
- Nov 2001
- Primary completion
- Dec 2007
- Modality
- Orthosteric Ligands
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial of lasofoxifene in postmenopausal osteoporosis (3 arms), sponsored by Ligand Pharmaceuticals. Primary endpoints: New morphometric vertebral fractures at 3 years, New cases of breast cancer at 5 years and 1 more. Started Nov 2001; status: completed.
02
Drugs
lasofoxifene
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00141323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141323.